Plasma sRAGE is not associated with urinary microalbumin excretion in type 2 diabetic nephropathy at the early stage

Diabetes Research and Clinical Practice

Volumn 87, Issue 2, 2010, Pages 157-160

  Yu, Jiang Yi ^a   An, Xiao Fei ^a   Liu, Jing Shun ^a   Ten, Shi Chao ^a   Wang, Xin ^a   Zhao, Yue ^a   Huang, Sha ^a   Gu, Wan Jian ^a   Gao, Feng ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Carboxymethyllysine; Diabetic nephropathy; sRAGE; Urinary microalbumin

Indexed keywords

6 N CARBOXYMETHYLLYSINE; ADVANCED GLYCATION END PRODUCT RECEPTOR;

ADULT; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE COURSE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL;

AGE OF ONSET; AGED; ALBUMINURIA; BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLOMERULAR FILTRATION RATE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; LIPIDS; LYSINE; MALE; MIDDLE AGED; PATIENT SELECTION; RECEPTORS, IMMUNOLOGIC;

EID: 74449090588     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2009.11.002     Document Type: Article

References (22)

1. Gross J.L., de Azevedo M.J., Silveiro S.P., Canani L.H., Caramori M.L., and Zelmanovitz T. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care 28 (2005) 164-176
2. Brownlee M., Cerami A., and Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N. Engl. J. Med. 318 (1988) 1315-1321
3. Sugimoto K., Yasujima M., and Yagihashi S. Role of advanced glycation end products in diabetic neuropathy. Curr. Pharm. Des. 14 (2008) 953-961
4. Yamamoto H., Watanabe T., Yamamoto Y., Yonekura H., Munesue S., Harashima A., et al. RAGE in diabetic nephropathy. Curr. Mol. Med. 7 (2007) 752-757
5. Sourris K.C., and Forbes J.M. Interactions between advanced glycation end-products (AGE) and their receptors in the development and progression of diabetic nephropathy-are these receptors valid therapeutic targets. Curr. Drug Targets 10 (2009) 42-50
6. Hanford L.E., Enghild J.J., Valnickova Z., Petersen S.V., Schaefer L.M., Schaefer T.M., et al. Purification and characterization of mouse soluble receptor for advanced glycation end products (sRAGE). J. Biol. Chem. 279 (2004) 50019-50024
7. Yonekura H., Yamamoto Y., Sakurai S., Petrova R.G., Abedin M.J., Li H., et al. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem. J. 370 (2003) 1097-1109
8. Katakami N., Matsuhisa M., Kaneto H., Matsuoka T.A., Sakamoto K., Nakatani Y., et al. Decreased endogenous secretory advanced glycation end product receptor in type 1 diabetic patients: its possible association with diabetic vascular complications. Diabetes Care 28 (2005) 2716-2721
9. Nin J.W., Ferreira I., Schalkwijk C.G., Prins M.H., Chaturvedi N., Fuller J.H., et al. Levels of soluble receptor for AGE are cross-sectionally associated with cardiovascular disease in type 1 diabetes, and this association is partially mediated by endothelial and renal dysfunction and by low-grade inflammation: the EURODIAB Prospective Complications Study. Diabetologia 52 (2009) 705-714
10. Humpert P.M., Kopf S., Djuric Z., Wendt T., Morcos M., Nawroth P.P., et al. Plasma sRAGE is independently associated with urinary albumin excretion in type 2 diabetes. Diabetes Care 29 (2006) 1111-1113
11. Humpert P.M., Djuric Z., Kopf S., Rudofsky G., Morcos M., Nawroth P.P., et al. Soluble RAGE but not endogenous secretory RAGE is associated with albuminuria in patients with type 2 diabetes. Cardiovasc. Diabetol. 6 (2007) 9
12. Sampson M.J., and Drury P.L. Accurate estimation of glomerular filtration rate in diabetic nephropathy from age, body weight, and serum creatinine. Diabetes Care 15 (1992) 609-612
13. Geroldi D., Falcone C., and Emanuele E. Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target. Curr. Med. Chem. 13 (2006) 1971-1978
14. dash;S American Diabetes Association. Standards of medical care in diabetes-2009. Diabetes Care 32 Suppl. 1 (2009) S13-S61
15. Forbes J.M., Thorpe S.R., Thallas-Bonke V., Pete J., Thomas M.C., Deemer E.R., et al. Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy. J. Am. Soc. Nephrol. 16 (2005) 2363-2372
16. Kanková K., Kalousová M., Hertlová M., Krusová D., Olsovský J., and Zima T. Soluble RAGE, diabetic nephropathy and genetic variability in the AGER gene. Arch. Physiol. Biochem. 114 (2008) 111-119
17. Nakamura K., Yamagishi S.I., Matsui T., Adachi H., Takeuchi M., and Imaizumi T. Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are correlated with AGEs in both diabetic and non-diabetic subjects. Clin. Exp. Med. 7 (2007) 188-190
18. Nakamura K., Yamagishi S., Adachi H., Matsui T., Kurita-Nakamura Y., Takeuchi M., et al. Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes. Microvasc. Res. 76 (2008) 52-56
19. Tan K.C., Shiu S.W., Chow W.S., Leng L., Bucala R., and Betteridge D.J. Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes. Diabetologia 49 (2006) 2756-2762
20. Tanji N., Markowitz G.S., Fu C., Kislinger T., Taguchi A., Pischetsrieder M., et al. Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J. Am. Soc. Nephrol. 11 (2000) 1656-1666
21. Yamagishi S., and Imaizumi T. Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) may reflect tissue RAGE expression in diabetes. Arterioscler. Thromb. Vasc. Biol. 27 (2007) e33-34
22. Grossin N., Wautier M.P., Meas T., Guillausseau P.J., Massin P., and Wautier J.L. Severity of diabetic microvascular complications is associated with a low soluble RAGE level. Diabetes Metab. 34 (2008) 392-395